November 28, 2016 - By Adrian Mccoy
Penny stock shareholders are becoming inquisitive about PHARMOS CORPORATION (OTCMKTS:PARS), following the fact that the share price has moved $-0.0025, reaching the $0.015 price level in a recent trade.
A big benefit of investing in small-cap shares is that there is a prospect to outpace the institutional investors. In addition, mutual funds have limits controlling their power to purchase large lots of any one firm’s outstanding shares.
It’s the latest price, but let’s analyze how the stock has been doing recently. In the past year, PHARMOS CORPORATION’s stock was big mover. According to the short interest report published recently, (PARS) had 2,500 shorted shares for 0.1 days to cover. The prior short interest was also unknown for a $N/A change. The 52-Week High and Low are noted here. -75.00% (High), Infinity, (Low). The stock had 43,300 average volume.
Is stock price of PHARMOS CORPORATION Set to Getaway to Their Potential? Register for Our Newsletter and Know the Inside Scoop!
As seen in stock market, the first point in investing in penny shares is to earn money. A popular trait of penny shares is that they move quickly and are extremely volatile. Penny shares are mainly stocks of small cap firms that can be open to change in industry conditions and stock market sentiments. Though penny shares are generally stated to be dicey, a trader can make massive amount of money in a short period of time, as against bigger, so-named ‘blue chip’ shares and mutual funds, which need a long-term plan.
Needless to state, investing in penny stock is not a right choice for the risk-averse, and only non-essential disposable income or ‘play money’ should be put in penny stocks. In no way are these stocks termed as the conservative investments and traders who play them are willing to take risks with invested capital. Penny stock shareholders must be prepared to put on stake their entire investment. Penny stocks trade fast in directions, recording massive downticks or upticks in few hours.
Receive Breaking Updates by Enrolling to our Newsletter! Hit on the Bar Below and Explore About Stocks that are Set to Make a Run!
Anticipated penny stock investors should learn and gain knowledge of the penny stock market. They must conduct intense research of a firm they might want to invest their money into. Learning can start by enrolling to a penny stock newsletter which offers informative penny stock recommendations. Gathering data as much as you can that is related to the penny stock world is tremendously vital if you want to earn money in trading. It is highly suggested that you enter into the market with a small amount of capital to lessen the risk if you incur a loss.
Disclaimer: The information, views, and opinions expressed in this publication are those of the writers and do not necessarily shows the position or official policy of any company financial professionals, analysts or stakeholders. Examples of assessment performed within this publication are just examples. They should not be used to make financial decisions or stock portfolio as they are based merely on open source and limited information. Assumptions taken within the study are not indicative of the position of any financial professionals or analysts.
More notable recent Pharmos Corporation (OTCMKTS:PARS) news were published by: Prnewswire.com which released: “Pharmos Provides Update on Ongoing Clinical Trial of Levotofisopam for the …” on April 05, 2012, also Businesswire.com with their article: “Millendo Therapeutics Announces Appointment of Three Vice Presidents” published on October 13, 2016, Globenewswire.com published: “BioBlast Pharma Enhances Leadership Team” on January 11, 2016. More interesting news about Pharmos Corporation (OTCMKTS:PARS) were released by: Seekingalpha.com and their article: “It’s Not Just About Getting High – Seven Marijuana Stocks” published on January 21, 2009 as well as Prnewswire.com‘s news article titled: “Global Neurotech Industry 2015-2016 Report: Market Analysis and Strategic …” with publication date: October 16, 2015.
Pharmos Corporation is a biopharmaceutical firm that discovers and develops therapeutics to treat a range of metabolic and nervous system disorders, including gout, disorders of the brain-gut axis, pain/inflammation and autoimmune disorders. The company has a market cap of $1.05 million. Pharmos owns the rights to both R and S Tofisopam. It currently has negative earnings. These are the two enantiomers of racemic tofisopam that has been used outside the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy